Biological context
MGF splice-product language
Mechano growth factor refers to an IGF-1 splice-variant context discussed in muscle adaptation. Papers may study transcripts, peptides or E-domain sequences.
Evidence profile · O-009
MGF / PEG-MGF: different molecules, preclinical evidence
PEGylation changes the evidence object. Mechanistic muscle-repair findings do not establish human performance benefit, and WADA prohibits mechano growth factors in sport.
MGF and PEG-MGF do not have dependable controlled human evidence for muscle growth, recovery or performance. The literature is mainly laboratory and animal research on an IGF-1 splice-product E-peptide or related constructs. Adding polyethylene glycol changes molecular properties, so unmodified MGF evidence cannot simply be assigned to PEG-MGF.
The 2026 WADA Prohibited List names mechano growth factors in the S2 growth-factor category, prohibited at all times. FDA also says it has not identified human exposure data for PEG-MGF drug products and notes immunogenicity and impurity concerns. Sport status, clinical evidence and vial identity are three different questions.
Molecule identity
MGF, an E-peptide and PEG-MGF are not interchangeable labels
Research construct
Synthetic E-peptide
A particular sequence used in cells or animals is a defined research object. Results apply to that construct and experiment.
Chemical modification
PEG-MGF
PEGylation can alter size, persistence, distribution, aggregation and immune risk. It creates a separate product-evidence question.
Evidence layer
What the preclinical studies show
| Model | Reported signal | What it can support | What it cannot support |
|---|---|---|---|
| Cultured satellite cells | Cell proliferation and senescence measures | A muscle-cell biology hypothesis | Human hypertrophy, strength or recovery |
| Animal cardiac injury | Cardiac function after experimental injury | Further preclinical investigation | Athletic performance or muscle gain |
| Rat tendon injury | Healing measures in a constructed injury model | A tendon-repair hypothesis | Clinical return-to-sport benefit |
| PEG-MGF products | No human exposure data identified by FDA | No clinical effect estimate | Safety or effectiveness claims |
Anti-doping
The 2026 WADA position is direct
WADA lists mechano growth factors within section S2, which covers peptide hormones, growth factors, related substances and mimetics. The category is prohibited at all times, in and out of competition.
Athletes are responsible for substances found in their samples under applicable anti-doping rules. A “research” label, uncertain purity or absence from an ingredient panel does not create an exemption. Rules and product composition can change, so athletes should use official anti-doping advice rather than seller assurances.
Product boundary
A purity result may still miss the identity question
A chromatogram can show a dominant peak without proving that the peak is the claimed sequence or PEGylated species. Suitable mass spectrometry, reference materials and orthogonal methods may be needed to distinguish unmodified peptide, PEGylation state, related variants and degradation products.
Chemical identity still does not establish sterility, endotoxin, container integrity, clinical benefit or anti-doping safety. FDA notes that PEG-MGF may present immunogenicity and peptide-impurity concerns and says it found no human exposure data.
Detection language deserves care. A paper may describe analytical characterisation of one reference material or the development of a method for a known target. That does not show that every laboratory uses the method, that every modified form is covered, or that an athlete can infer clearance from a negative private test. Anti-doping status comes from the rule, not from a seller’s claim about detectability.
SequenceWhich peptide is present
ModificationPEGylation state and distribution
MicrobiologySeparate methods required
SportCurrent rules govern
Decision boundary
What remains unknown
A credible human programme would have to define the exact sequence and modification before it could test an outcome. “MGF” is not precise enough for a protocol, analytical method or safety record. Human muscle mass, strength, recovery time and tendon healing would also require separate trials rather than one performance label.
- Whether any MGF construct improves human muscle, strength, recovery or tendon outcomes.
- How a claimed PEG-MGF product behaves in people.
- The frequency of immune, metabolic or other harms after human exposure.
- Whether a vial contains the claimed sequence and PEGylated form.
- Whether its impurities, aggregates, sterility, endotoxin and stability are controlled.
- How a specific anti-doping laboratory would detect and identify a modified species.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| WADA: 2026 Prohibited List | Mechano growth factors are named in the S2 category, prohibited at all times. | The list does not verify a product’s contents or describe every detection method. | |
| FDA: bulk-substance safety risks | FDA reports no identified human exposure data for PEG-MGF and notes immunogenicity and impurity concerns. | It does not analyse a specific vial or establish an adverse-event rate. | |
| PubMed: MGF E-peptide and satellite cells | A cell study reported changes in proliferative lifespan and senescence measures. | Cultured cells do not establish muscle growth or performance in people. | |
| PubMed: MGF and cardiac injury | Preclinical research reported a cardiac signal after experimental injury. | It does not establish human recovery, hypertrophy or safety. | |
| PubMed: mass-spectrometric characterisation of MGF | Analytical research shows the need to characterise peptide forms and supports anti-doping method development. | A method paper does not prove a consumer vial is correctly labelled. |
Continue the investigation
Read the connected evidence
- whether testing distinguishes the modified formSee which analytical questions require sequence and modification-specific methods.
- peptide muscle-growth and performance claimsCompare MGF with secretagogues and IGF-1 analogues at the outcome level.
- the current WADA prohibited classesRead the sport rules without treating detectability as permission.
- known versus unknown risksSeparate no human exposure data from a claim of safety.
Quick answers
Frequently asked questions
Does MGF build muscle in people?
No dependable controlled human evidence establishes greater muscle mass, strength or performance. The supporting literature is preclinical.
Is PEG-MGF the same as MGF?
No. PEGylation changes molecular properties and creates a separate identity, exposure, safety and effectiveness question.
Is MGF prohibited in sport?
Yes. The 2026 WADA Prohibited List names mechano growth factors in section S2, prohibited at all times.
Has PEG-MGF been tested in people?
FDA says it has not identified human exposure data for drug products containing PEG-MGF by any route.
Can a purity test distinguish PEG-MGF?
Not necessarily. Method suitability, mass information, reference material and orthogonal confirmation matter, and PEGylation may create heterogeneous species.
What remains unknown?
Human benefit, human safety, product identity and how specific modified forms are detected remain uncertain.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-009, MGF and PEG-MGF evidence, identity and sport status was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.